Kurtis Bülent, Tüter Gilay, Serdar Muhittin, Pinar Selin, Demirel Ilkim, Toyman Utku
Department of Periodontology, Faculty of Dentistry, Gazi University, Ankara, Turkey.
J Periodontol. 2007 Oct;78(10):1954-61. doi: 10.1902/jop.2007.070149.
Cigarette smoking has been identified as an important risk factor for the initiation and progression of chronic periodontitis (CP). The aim of this study was to investigate the effects of phase I periodontal therapy and adjunctive flurbiprofen administration on matrix metalloproteinase (MMP)-8 levels in gingival crevicular fluid (GCF) samples from smoking and non-smoking patients with CP.
Twenty-nine non-smoking and 29 smoking patients with CP were divided into four groups according to periodontal treatment modalities. Group 1 (non-smokers with CP) and group 3 (smokers with CP) patients received daily 100-mg flurbiprofen tablets in a 2 x 1 regimen for 10 days together with scaling and root planing (SRP). Patients in group 2 (non-smokers with CP) and group 4 (smokers with CP) received placebo tablets in a 2 x 1 regimen for 10 days together with SRP. Plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment level (CAL) measurements were recorded; GCF samples were collected from each sampling area at baseline and after the 10-day period of drug intake by a single examiner who was unaware of the treatment modality. Assays for GCF MMP-8 were carried out by an enzyme-linked immunosorbent assay.
All groups showed statistically significant reductions in PI and GI scores following the phase I periodontal treatment (P < 0.05), but no statistical differences were observed in PD and CAL scores after therapy. In all groups, the reduction of GCF MMP-8 levels after therapy was statistically significant compared to baseline levels (P < 0.001). When groups 1 and 3 and 2 and 4 were compared according to GCF MMP-8 levels after the therapy, no statistically significant differences were observed (P = 0.117 and P = 0.485, respectively).
Flurbiprofen administration had no additional inhibitory effect over SRP alone on GCF levels of MMP-8 in smokers compared to non-smokers with CP.
吸烟已被确认为慢性牙周炎（CP）发病和进展的重要危险因素。本研究的目的是调查一期牙周治疗及辅助使用氟比洛芬对吸烟和不吸烟的CP患者龈沟液（GCF）样本中基质金属蛋白酶（MMP）-8水平的影响。
29名不吸烟和29名吸烟的CP患者根据牙周治疗方式分为四组。第1组（不吸烟的CP患者）和第3组（吸烟的CP患者）每日服用100毫克氟比洛芬片，采用2×1方案，共10天，同时进行龈上洁治和根面平整（SRP）。第2组（不吸烟的CP患者）和第4组（吸烟的CP患者）服用安慰剂片，采用2×1方案，共10天，同时进行SRP。记录菌斑指数（PI）、牙龈指数（GI）、探诊深度（PD）和临床附着水平（CAL）测量值；在基线和服药10天后，由一名不了解治疗方式的检查者从每个采样区域收集GCF样本，并通过酶联免疫吸附测定法检测GCF中的MMP-8。
所有组在一期牙周治疗后PI和GI评分均有统计学意义的降低（P<0.05），但治疗后PD和CAL评分无统计学差异。所有组治疗后GCF中MMP-8水平较基线水平均有统计学意义的降低（P<0.001）。根据治疗后GCF中MMP-8水平比较第1组和第3组以及第2组和第4组时，未观察到统计学差异（分别为P=0.117和P=0.485）。
与不吸烟的CP患者相比，氟比洛芬对吸烟CP患者GCF中MMP-8水平的抑制作用并不比单独的SRP更强。
